A ginger active ingredient composition and use thereof

Abstract

This invention provides a ginger active ingredient composition and its application. The ginger active ingredient composition includes acetylated 12-gingerol, 8-gingereneol, and 10-gingereneol in a mass ratio of (1-3):2:(2-3). The ginger active ingredient composition of this invention can improve glucose tolerance, increase insulin sensitivity, reduce serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels, increase high-density lipoprotein levels, reduce the activity of hepatic alanine aminotransferase and aspartate aminotransferase, improve the degree of hepatic fat vacuolar lesions, and reduce the content of lipid metabolism-related metabolites in obese individuals. Simultaneously, acetylation of 12-gingerol improves its lipid solubility, enhances cell membrane penetration, reduces oxidative degradation of phenolic hydroxyl groups, and improves stability. Furthermore, it releases free 12-gingerol after enzymatic hydrolysis, achieving a sustained-release effect.

Description

Technical Field

[0001] This invention belongs to the fields of health products and pharmaceutical technology, specifically relating to a composition of active ginger ingredients and its application. Background Technology

[0002] Obesity, as a prevalent metabolic disorder, has a profound impact on global public health. Obesity is not simply a matter of weight gain; its severity lies in its ability to trigger diseases such as heart disease, diabetes, hypertension, and kidney failure, making it the "root cause" of many ailments. Hyperlipidemia is one of the complications of obesity, characterized by high levels of triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C). Elevated levels of these lipid markers further lead to abnormal lipid metabolism, inducing fatty liver disease. Fatty liver, in turn, affects lipid metabolism, exacerbating hyperlipidemia and obesity, thus creating a vicious cycle. Therefore, how to effectively prevent and treat obesity is a hot research topic in metabolic disorders.

[0003] Currently, existing anti-obesity drugs are ineffective due to tolerability and significant chronic toxic side effects, while many traditional herbal extracts hold promise as safe and effective alternative therapies for obesity. Ginger is one of the most common spices, containing many phenolic compounds that have shown beneficial properties for human health, including enhancing digestion, reducing inflammation, vomiting, cancer, and metabolic syndrome. Ginger's anti-obesity effect is mainly attributed to gingerol, the most abundant bioactive compound. Current research focuses primarily on components such as 6-gingerol and 6-shogaol, while the efficacy of long-chain gingerols like 8-shogaol and 10-shogaol in improving diabetes, hypertension, and non-alcoholic fatty liver disease, as well as their effects on lipid-related metabolites, have not yet been reported. Summary of the Invention

[0004] Technical problem to be solved: In view of the above problems, the purpose of this invention is to provide a ginger active ingredient composition and its application, and to explore the preventive and therapeutic effects of acetylated 12-gingerol, 8-gingereneol and 10-gingereneol on weight gain, fat accumulation, hyperlipidemia and lipid-related metabolites in obese mice induced by a high-fat diet, so as to provide a new perspective for the fields of biomedicine and health products in the treatment of obesity, hyperlipidemia, non-alcoholic fatty liver and chronic metabolic disorders.

[0005] Technical solution: A composition of active ginger ingredients, comprising acetylated 12-gingerol, 8-gingereneol and 10-gingereneol.

[0006] Furthermore, the mass ratio of the acetylated 12-gingerol, 8-gingereneol and 10-gingereneol is (1-3):2:(2-3).

[0007] Furthermore, the preparation method of the acetylated 12-gingerol is as follows:

[0008] S1: Under nitrogen protection, mix 1-1.2 mmol of 12-gingerol and 10-15 mL of anhydrous dichloromethane, add 1.0-1.2 mmol of pyridine dropwise, and stir to dissolve;

[0009] S2: Slowly add 1.5-2.0 mmol of acetic anhydride and stir the reaction at 25℃ for 4-6 hours;

[0010] S3: Add 10-20 mL of ice water to quench the reaction, and collect the organic phase by liquid-liquid separation;

[0011] S4: Wash the organic phase with saturated NaHCO3 solution and then dry it with anhydrous Na2SO4;

[0012] S5: The solvent was removed by rotary evaporation, and the crude product was purified by silica gel column chromatography to obtain acetylated 12-gingerol.

[0013] Furthermore, the silica gel column chromatography is performed using a petroleum ether / ethyl acetate gradient elution.

[0014] The use of the above-mentioned ginger active ingredient composition in the preparation of drugs for the prevention and / or treatment of obesity.

[0015] Furthermore, the drug is a drug that improves glucose tolerance in obese individuals, increases insulin sensitivity, reduces triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels, and increases high-density lipoprotein levels.

[0016] Furthermore, the drug is a drug that improves liver cell morphology, slows down the accumulation of lipids in the liver, downregulates liver alanine aminotransferase (ALT) activity, aspartate aminotransferase (AST) activity, and improves the degree of liver fat vacuolar lesions.

[0017] Furthermore, the drug is a drug that regulates the levels of lipid metabolism-related metabolites in obese individuals.

[0018] Furthermore, the metabolites related to regulating lipid metabolism in obese individuals include (20R,22R)-20,22-dihydroxycholesterol, galactose-1-phosphate, glycerophosphate choline, lysophosphatidylcholine (18:3), docosahexaenoic acid, lysophosphatidylcholine (20:3(8Z,11Z,14Z)), phosphatidylcholine (17:0), phosphatidylcholine (20:0), phosphatidylcholine (18:1(11Z)), phosphatidylcholine (16:1(9Z) / 0:0), (20R,22R)-20,22-dihydroxycholesterol, galactose-1-phosphate, sphingosine-phosphate, and bile acids. Beneficial effects

[0019] 1. This invention uses acetylated 12-gingerol, 8-gingereneol and 10-gingereneol to form a composition. Through a triple mechanism of "blocking-regulating-enhancing", it blocks fat absorption, regulates inflammation / oxidative stress and enhances energy consumption. Combined with precise proportions, it achieves a synergistic anti-obesity effect that is superior to that of a single ingredient.

[0020] 2. In this invention, acetylated 12-gingerol primarily reduces lysophosphatidylcholine and glycerophosphocholine, directly intervening in phospholipid metabolism disorders, activating AMPK (energy sensor), and inhibiting mTOR (lipid synthesis signal); 8- / 10-gingerol primarily downregulates the pro-inflammatory mediator leukotriene D4 and the oxidative stress marker adrenaline, alleviating systemic inflammation, and indirectly enhancing AMPK activity through ROS regulation, forming a positive feedback loop.

[0021] 3. In this invention, 12-gingerol is acetylated. Natural 12-gingerol has low intestinal absorption due to the hydrophilicity of its hydroxyl groups. Acetylation improves its lipid solubility, enhances cell membrane penetration, reduces oxidative degradation of the phenolic hydroxyl groups, and improves stability. Furthermore, it releases free 12-gingerol after enzymatic hydrolysis, achieving a sustained-release effect. Simultaneously, the acetylated structure enhances the inhibition of lipase, reduces the breakdown and absorption of dietary fat, and directly intervenes in the lipid intake process in obesity.

[0022] 4. The ginger active ingredient composition of the present invention can improve glucose tolerance, increase insulin sensitivity, reduce the content of serum triglycerides, total cholesterol and low-density lipoprotein cholesterol, increase the content of high-density lipoprotein, reduce the activity of liver alanine aminotransferase and aspartate aminotransferase, and improve the degree of liver fat vacuolar lesions.

[0023] 5. The ginger active ingredient composition of the present invention can regulate the content of lipid pathway-related (20R,22R)-20,22-dihydroxycholesterol, galactose-1-phosphate, glycerophosphate choline, lysophosphatidylcholine (18:3), docosahexaenoic acid, lysophosphatidylcholine (20:3(8Z,11Z,14Z)), phosphatidylcholine (17:0), phosphatidylcholine (20:0), phosphatidylcholine (18:1(11Z)), phosphatidylcholine (16:1(9Z) / 0:0), (20R,22R)-20,22-dihydroxycholesterol, galactose-1-phosphate, sphingosine-phosphate and bile acid. Attached Figure Description

[0024] Figure 1 Figure 4 shows the results of the glucose homeostasis and insulin resistance experiments in mice in Examples 4-5 and Comparative Examples 3-6. Figure (A) shows the results of the glucose tolerance test, and Figure (B) shows the results of the insulin tolerance test.

[0025] Figure 2Figures showing the mouse adipose tissue weight index results of Examples 4-5 and Comparative Examples 3-6;

[0026] Figure 3 The images show the results of the hematoxylin-eosin staining experiment on mouse adipocytes in Examples 4-5 and Comparative Examples 3-6.

[0027] Figure 4 Figure 4 shows the experimental results of mouse serum indicators in Examples 4-5 and Comparative Examples 3-6. Figure (A) shows total cholesterol in mouse serum, Figure (B) shows triglycerides in mouse serum, Figure (C) shows low-density lipoprotein cholesterol in mouse serum, and Figure (D) shows high-density lipoprotein cholesterol in mouse serum.

[0028] Figure 5 Figure 4 shows the experimental results of mouse liver-related indices and pathological sections in Examples 4-5 and Comparative Examples 3-6. Figure (A) shows alanine aminotransferase in mouse serum, Figure (B) shows aspartate aminotransferase in mouse serum, and Figure (C) shows representative H&E staining images of liver sections. Detailed Implementation

[0029] This invention proposes a ginger active ingredient composition and its application. To make the objectives, technical solutions, and effects of this invention clearer and more explicit, the following will provide a more detailed description of the invention in conjunction with specific examples. It should be understood that the specific examples described herein are only for explaining the invention and are not intended to limit the invention.

[0030] The 8-shogaol, 10-shogaol, and 12-shogaol used in the following tests are all standards with a purity > 98%. Example 1

[0031] The preparation method of acetylated 12-gingerol is as follows:

[0032] S1: Under nitrogen protection, mix 1 mmol of 12-gingerol and 10 mL of anhydrous dichloromethane, add 1.2 mmol of pyridine dropwise, and stir to dissolve;

[0033] S2: Slowly add 1.5 mmol of acetic anhydride and stir the reaction at 25°C for 5 hours;

[0034] S3: Add 10 mL of ice water to quench the reaction, and collect the organic phase by liquid-liquid separation;

[0035] S4: Wash the organic phase with saturated NaHCO3 solution and then dry it with anhydrous Na2SO4;

[0036] S5: The solvent was removed by rotary evaporation, and the crude product was purified by silica gel column chromatography using a petroleum ether / ethyl acetate gradient elution to obtain acetylated 12-gingerol.

[0037] The purity of acetylated 12-gingerol was determined to be 98.8%. Example 2

[0038] Preparation of ginger active ingredient composition supplement 1: Acetylated 12-gingerol, 8-gingereneol and 10-gingereneol were compounded in a mass ratio of 2:2:3 and dissolved in 0.5% carboxymethyl cellulose solution to obtain supplement 1. Example 3

[0039] Preparation of ginger active ingredient composition supplement 2: Acetylated 12-gingerol, 8-gingereneol and 10-gingereneol were compounded in a mass ratio of 3:2:3 and dissolved in 0.5% carboxymethyl cellulose solution to obtain supplement 2.

[0040] Comparative Example 1: No acetylated 12-gingerol added

[0041] Preparation of ginger active ingredient composition supplement 3: 8-shogaol and 10-shogaol were compounded at a mass ratio of 2:3 and dissolved in 0.5% carboxymethyl cellulose solution to obtain supplement 3.

[0042] Comparative Example 2: Replacing acetylated 12-gingerol with 12-gingerol

[0043] Preparation of ginger active ingredient composition supplement 4: 12-gingerol, 8-gingereneol and 10-gingereneol were compounded in a mass ratio of 3:2:3 and dissolved in 0.5% carboxymethyl cellulose solution to obtain supplement 4.

[0044] The composition of the experimental diet is shown in Table 1 below:

[0045] Table 1

[0046] Components Normal diet group (NCD) / % High-fat diet group (HFD) / % Casein 18.95 25.85 L-cysteine 0.28 0.39 corn starch 42.89 0 sucrose 16.75 9.4 maltodextrin 7.1 16.15 Cellulose 4.74 6.46 Soybean oil 2.37 3.23 lard 1.89 31.67 minerals 4.74 6.46 tartrate choline 0.19 0.26 Vitamins 0.1 0.13 Example 4

[0047] The specific steps for mouse grouping, model establishment, and drug administration, by weight, are as follows:

[0048] S1. Mouse grouping: The experimental animals were SPF-grade male C57BL / 6J mice, 7 weeks old, with an ambient temperature of 23±2°C, humidity of 50±10%, and 12-hour light-dark alternation. After 1 week of acclimatization culture, a 16-week dietary intervention was implemented.

[0049] S2. Modeling and administration: Mice were fed supplement 1 by gavage at a dose of 50 mg / kg body weight, and were fed according to the high-fat diet group. Example 5

[0050] The specific steps for mouse grouping, model establishment, and drug administration, by weight, are as follows:

[0051] S1. Mouse grouping: The experimental animals were SPF-grade male C57BL / 6J mice, 7 weeks old, with an ambient temperature of 23±2°C, humidity of 50±10%, and 12-hour light-dark alternation. After 1 week of acclimatization culture, a 16-week dietary intervention was implemented.

[0052] S2. Modeling and administration: Mice were fed supplement 2 by gavage at a dose of 50 mg / kg body weight, and were fed according to the high-fat diet group. Comparative Example 3

[0053] The specific steps for mouse grouping, model establishment, and drug administration, by weight, are as follows:

[0054] S1. Mouse grouping: The experimental animals were SPF-grade male C57BL / 6J mice, 7 weeks old, with an ambient temperature of 23±2°C, humidity of 50±10%, and 12-hour light-dark alternation. After 1 week of acclimatization culture, a 16-week dietary intervention was implemented.

[0055] S2. Modeling and administration: Mice were fed supplement 3 by gavage at a dose of 50 mg / kg body weight, and were fed according to the high-fat diet group. Comparative Example 4

[0056] The specific steps for mouse grouping, model establishment, and drug administration, by weight, are as follows:

[0057] S1. Mouse grouping: The experimental animals were SPF-grade male C57BL / 6J mice, 7 weeks old, with an ambient temperature of 23±2°C, humidity of 50±10%, and 12-hour light-dark alternation. After 1 week of acclimatization culture, a 16-week dietary intervention was implemented.

[0058] S2. Modeling and administration: Mice were fed supplement 4 by gavage at a dose of 50 mg / kg body weight, and were fed according to the high-fat diet group.

[0059] Comparative Example 5 HFD Group

[0060] The specific steps for mouse grouping, model establishment, and drug administration are as follows:

[0061] S1. Mouse grouping: The experimental animals were SPF-grade male C57BL / 6J mice, 7 weeks old, with an ambient temperature of 23±2°C, humidity of 50±10%, and 12-hour light-dark alternation. After 1 week of acclimatization culture, a 16-week dietary intervention was implemented.

[0062] S2. Mice were fed the same high-fat diet as the control group, without any medication.

[0063] Comparative Example 6 NCD Group

[0064] The specific steps for mouse grouping, model establishment, and drug administration are as follows:

[0065] S1. Mouse grouping: The experimental animals were SPF-grade male C57BL / 6J mice, 7 weeks old, with an ambient temperature of 23±2°C, humidity of 50±10%, and 12-hour light-dark alternation. After 1 week of acclimatization culture, a 16-week dietary intervention was implemented.

[0066] S2. Mice were fed the same diet as the normal diet group without any medication.

[0067] Performance testing

[0068] (1) Determination of glucose tolerance and insulin resistance in obese mice

[0069] Two weeks prior to sample collection, mice were fasted for 12 hours, and blood was collected by surgically cutting their tails using sterile methods. Fasting blood glucose levels were measured using a glucometer and used as the initial value (0 min) for the oral glucose tolerance test (OGTT). Mice were administered glucose solution by gavage, and blood glucose levels were measured at 20, 40, 60, 80, 100, and 120 min after gavage. Similarly, mice were administered insulin via intraperitoneal injection, and blood glucose levels were measured at 20, 40, 60, 80, 100, and 120 min.

[0070] from Figure 1 It can be seen that a high-fat diet can increase fasting blood glucose in mice, but the intervention of the ginger active ingredient combination showed a blood glucose control effect. Figure 1 As shown in (A), in Comparative Example 6, the blood glucose level in mice peaked 15 minutes after intraperitoneal injection of glucose, gradually decreasing over time and returning to normal after 120 minutes. In contrast, the blood glucose peak in obese mice of Comparative Example 5 occurred at 30 minutes, with a prolonged period of hyperglycemia and a slow decline; it did not return to normal after 120 minutes, and the area under the curve (AUC) was also increased. The different proportions of ginger active ingredient compositions in Comparative Examples 3-4 and Examples 4-5 significantly improved glucose tolerance in mouse blood. The blood glucose change curves in Examples 4-5 showed a similar trend to Comparative Example 6, and the AUC in Example 5 was significantly lower than that in Comparative Example 5. This indicates that the ginger active ingredient composition containing acetylated 12-gingerol can effectively improve glucose tolerance in obese mice. Furthermore, the lower AUC in Example 5 compared to Comparative Example 4 suggests that acetylated 12-gingerol is more effective than 12-gingerol.

[0071] There is a close and important relationship between insulin tolerance and blood glucose. Insulin is the only hormone in the body that lowers blood glucose; it maintains stable blood glucose levels by promoting the uptake and utilization of glucose by cells while reducing gluconeogenesis. An insulin tolerance test is an experiment that measures insulin function by observing changes in blood glucose levels after an intravenous injection of a certain amount of insulin to assess the effectiveness of insulin. Figure 1 As shown in (B), in Comparative Example 6 mice, after insulin injection, blood glucose concentration decreased rapidly within 15 to 30 minutes compared to fasting levels, and returned to fasting blood glucose levels within 60 to 90 minutes. This indicates that insulin can function normally to regulate blood glucose levels, while the glucose concentration in the obese mice of Comparative Example 5 decreased slowly and rose rapidly.

[0072] Compared with Comparative Example 5, the mice in Comparative Examples 3-4 and Examples 4-5 showed improved insulin tolerance and greater sensitivity to insulin, and the area under the curve (AUC) in Example 5 was significantly lower than that in Comparative Example 5. Therefore, the ginger active ingredient composition containing acetylated 12-gingerol can effectively prevent insulin resistance in mice.

[0073] (2) Adipose tissue experiment in obese mice

[0074] Mice were fasted for 24 hours after being administered oral gavage for 14 weeks, then anesthetized with CO2 and euthanized by cervical dislocation. Inguinal adipose tissue, epididymal adipose tissue, and perirenal white adipose tissue were harvested, and their weights were recorded. The percentage of adipose tissue weight to body weight was calculated as the adipose tissue index.

[0075] from Figure 2 As can be seen, after 14 weeks of intervention in Example 1, compared with the mice in Comparative Example 6, the weights of inguinal adipose tissue, epididymal adipose tissue, and perirenal adipose tissue in mice in Comparative Examples 3-5 and Examples 4-5 were significantly increased. The increase in Example 4-5 was less pronounced than that in Comparative Example 5. The results indicate that the ginger active ingredient composition can effectively inhibit the increase in body fat content in obese mice induced by a high-fat diet.

[0076] (3) Observation of epididymal adipocytes of obese mice after hematoxylin-eosin staining.

[0077] The collected epididymal adipose tissue was fixed in 10% paraformaldehyde solution and dehydrated sequentially with 80%, 90%, 95%, and 100% ethanol. After clearing with xylene, it was embedded in paraffin and sectioned. The sections were then destained sequentially with xylene for 20 min, anhydrous ethanol for 5 min, 75% ethanol for 5 min, and tap water, followed by staining in hematoxylin for 3-5 min. After eosin staining for 5 min, the sections were destained and cleared sequentially with anhydrous ethanol for 5 min and xylene for 5 min, and finally mounted with neutral resin. The pathological characteristics of the epididymal adipocytes were observed using an electron microscope.

[0078] from Figure 3 It can be seen that after 14 weeks of intervention, compared with Comparative Example 6 mice, the diameter of epididymal adipocytes in Comparative Example 5 mice was significantly larger, and the number of adipocytes within the same field of view was significantly reduced. Compared with Comparative Example 5 mice, the diameter of epididymal adipocytes in mice of Examples 4-5 was significantly smaller, and the number of adipocytes within the same field of view was significantly increased. These results indicate that the ginger active ingredient composition containing acetylated 12-gingerol can significantly reduce the diameter of epididymal adipocytes.

[0079] (4) Determination of relevant indicators in the serum of obese mice

[0080] Mice administered the drug via gavage for 14 weeks were fasted for 24 hours, then anesthetized with CO2 in a closed cage, and blood was collected from the peritoneum. After standing at room temperature for 1 hour, the serum was collected by centrifugation at 3000 rpm for 15 minutes. The levels of triglycerides, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol in the serum were measured using a kit.

[0081] from Figure 4 As can be seen, after 14 weeks of intervention, compared with Comparative Example 6, the serum levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol in Comparative Example 5 mice were significantly increased. However, compared with Comparative Example 5, the serum levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol in Comparative Examples 3-4 and Examples 4-5 mice were significantly decreased. These results indicate that the ginger active ingredient composition can effectively reduce lipid-related indicators in the serum of obese mice induced by a high-fat diet.

[0082] (5) Effects of obese mice on liver-related indices and observation of their pathological sections

[0083] Mice that had been administered oral gavage for 14 weeks were fasted for 24 hours, anesthetized with CO2, and blood was drawn from their abdominal cavity. They were then euthanized by cervical dislocation, and liver tissue was harvested and weighed. The liver was divided into two parts, one of which was immersed in 4% paraformaldehyde tissue fixative. Simultaneously, hematoxylin-eosin staining was performed on the sections for observation.

[0084] from Figure 5 (A) and Figure 5 (B) It can be seen that, compared with Comparative Example 5 mice, the serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in Comparative Example 3-4 and Example 4-5 mice were significantly reduced. From Figure 5 (C) It can be seen that the hematoxylin-eosin staining results under the optical microscope show that the mouse liver cells of Comparative Example 5 have obvious lipid vacuolar lesions, with a large total lipid vacuolar area and unclear cell boundaries and morphology. In contrast, the mouse liver cells of Comparative Examples 3-4 and Examples 4-5 have clear and regular boundaries and morphology, and fewer lipid vacuolar lesions.

[0085] (6) Non-targeted metabolomics analysis to detect serum metabolites

[0086] Untargeted metabolomics analysis was performed on the plasma samples from Examples 5 and 5. 100 μL of serum sample was extracted using 400 μL methanol and acetonitrile solution at a 1:1 volume ratio. The resulting mixture was sonicated at 40 kHz and 5°C for 30 min, followed by protein precipitation at -20°C for 30 min. The protein was then separated from the supernatant by centrifugation at 13000 g and 4°C for 15 min. The supernatant was then dried with a gentle nitrogen stream and sonicated in a 5°C water bath. The supernatant was then reconstituted in a loading solution of acetonitrile and water at a 1:1 volume ratio. The obtained metabolites were centrifuged at 13000 g and 4°C for 15 min, followed by LC-MS / MS analysis. Quality control samples (QC) were prepared by mixing equal volumes of all samples. LC-MS analysis was performed using a UHPLC-Q Exactive HF-X system equipped with an HSS T3 column, with data acquisition performed in positive or negative ion mode (70–1050 m / z). Raw data were processed using Progenesis QI software to eliminate false positive and internal standard peaks. Metabolites were identified using the HMDB, Metlin, and Majorbio databases. Differentially expressed metabolites were selected based on the importance of variables (VIP) in the projection obtained from the OPLS-DA model (VIP>1, P<0.05). Fisher's exact test was used for enrichment and pathway analysis of these metabolites. The results are shown in Table 2 below.

[0087] Table 2. Differences in lipid metabolism-related metabolites between Example 5 and Comparative Example 5

[0088] Metabolites Regulatory function p-value (20R,22R)-20,22-Dihydroxycholesterol Upward 1.37E-05 Galactose-1-phosphate Upward 0.00551 glycerophosphate choline Lower 2.43E-05 Lysophosphatidylcholine (18:3) Lower 0.000234 docosahexaenoic acid Lower 4.01E-06 Lysophosphatidylcholine (20:3(8Z,11Z,14Z)) Lower 3.62E-05 Phosphatidylcholine (17:0) Lower 9.66E-06 Phosphatidylcholine (20:0) Lower 8.90E-05 Phosphatidylcholine (18:1(11Z)) Lower 0.001717 Phosphatidylcholine (16:1(9Z) / 0:0) Lower 8.14E-07 (20R,22R)-20,22-Dihydroxycholesterol Upward 1.37E-05 Galactose-1-phosphate Upward 0.00551 Sphingosine-phosphate Upward 0.001638 cholic acid Lower 2.53E-06

[0089] The results showed that a total of 7776 positive ion peaks and 6344 negative ion peaks were identified, and 782 ion peaks were identified as metabolites, of which 477 positive ions and 305 negative ions corresponded to known metabolites. Table 2 shows that, comparing the lipid metabolism-related metabolites in Example 5 and Comparative Example 5, it was found that compared with Comparative Example 5 mice, 9 metabolites were significantly downregulated, while 5 metabolites showed significant upregulation.

[0090] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any way. Any person skilled in the art can make many possible variations and modifications to the technical solutions of the present invention, or modify them into equivalent embodiments, without departing from the spirit and technical essence of the present invention. Therefore, any simple modifications, equivalent substitutions, equivalent changes, and modifications made to the above embodiments based on the technical essence of the present invention, without departing from the content of the technical solutions of the present invention, shall still fall within the scope of protection of the present invention.

Claims

1. A composition of active ginger ingredients, characterized in that, It is composed of acetylated 12-gingerol, 8-gingereneol and 10-gingereneol; the mass ratio of acetylated 12-gingerol, 8-gingereneol and 10-gingereneol is 1-3:2:2-3. The preparation method of the acetylated 12-gingerol is as follows: S1: Under nitrogen protection, mix 1 mmol of 12-gingerol and 10 mL of anhydrous dichloromethane, add 1.2 mmol of pyridine dropwise, and stir to dissolve; S2: Slowly add 1.5 mmol of acetic anhydride and stir the reaction at 25°C for 5 hours; S3: Add 10 mL of ice water to quench the reaction, and collect the organic phase by separation; S4: Wash the organic phase with saturated NaHCO3 solution and then dry it with anhydrous Na2SO4; S5: The solvent was removed by rotary evaporation, and the crude product was purified by silica gel column chromatography using a petroleum ether / ethyl acetate gradient elution to obtain acetylated 12-gingerol.

2. The use of the ginger active ingredient composition according to claim 1 in the preparation of a drug for the prevention and / or treatment of obesity.

Images